
Applied Organometallic Chemistry p. 135 - 141 (2010)
Update date:2022-08-11
Topics:
Pinoie, Vanja
Biesemans, Monique
Willem, Rudolph
The present study investigates the suitability of a HypoGel support bearing oligomeric poly(ethylene glycol) (PEG) chains to act as an insoluble carrier for grafted organotin catalysts. Through the introduction of polar spacers, an improved swelling and site accessibility in the polar media typically involved in transesterification reactions are targeted. Advanced structural investigation shows that quantitative conversion into the targeted HypoGel-supported organotin trichloride is hampered by the existence of intra-and/or intermolecular donor-acceptor O → Sn interactions caused by the presence of donor moieties in the PEG-linker. Support is provided to the proposal that the latter interactions are at the origin of the moderate catalytic performance displayed by these HypoGel-supported catalysts, achieving only 41% conversion after 2 hours in the transesterification of ethyl acetate and n-octanol. In contrast with similar organotin catalysts supported by an alkyl spacer, the HypoGel-supported materials appear to be poorly recyclable and display poor leaching resistance. Copyright
View More
Anhui New Star Pharmaceutical Development Co., Ltd
Contact:013956922763
Address:Floor 3, F9A, F Workshop, No.110 Kexue Road, High-Tech Development Zone, Hefei, Anhui ,China
LinHai Cina Chemical Co., LTD.
Contact:0576-85580989
Address:Pharma-chem zone,Duqiao,Linhai,Zhejiang,China
Contact:86-21-34622192,13917187091,21-34622765
Address:No. 500 Caobao Road Shanghai P.R China
Suzhou Wedo Chemicals Co., Ltd.
Contact:86 512 58100425
Address:Zonger Road, DongSha Industry Park , Zhangjiagang, Jiangsu, China
website:http://www.uvchemkeys.com
Contact:0086-021-58785816
Address:RM2607 Building No.1 Guosheng, Lane 388, Zhongjiang Road, Putuo District, Shanghai 200062 China
Doi:10.1021/ac60351a037
(1975)Doi:10.1021/acs.joc.9b02962
(2020)Doi:10.1246/cl.2005.930
(2005)Doi:10.1021/ja01194a043
()Doi:10.1021/jp045671o
(2005)Doi:10.1021/acs.molpharmaceut.7b00871
(2018)